Comparing adherence and persistence of common selective serotonin reuptake inhibitors in veterans with major depressive disorder: a retrospective analysis of Veterans Affairs healthcare data [0.03%]
退伍军人重大抑郁障碍选择性血清素再摄取抑制剂坚持度和依从性的比较：退伍军人健康管理局医疗数据的回顾性分析
Ryan D Pittman
Ryan D Pittman
Depression has a high prevalence and increasing incidence in the USA. Antidepressants, particularly selective serotonin reuptake inhibitors (SSRIs), are the most commonly used treatments. To be effective, SSRIs must be taken consistently. T...
Suicide behind bars: time to tackle barriers to mental healthcare access in prisons [0.03%]
监狱中的自杀问题：是时候解决囚犯获得精神卫生服务的障碍了
Yasin Hasan Balcioglu
Yasin Hasan Balcioglu
An algorithmic approach to the case management of patients diagnosed with schizophrenia and substance use disorders: what is the evidence? [0.03%]
精神分裂症和物质使用障碍患者的病例管理的算法方法有哪些证据？
Octavian Vasiliu
Octavian Vasiliu
Lumateperone monotherapy for major depressive episodes associated with bipolar disorder: efficacy and safety in a randomized placebo-controlled trial [0.03%]
用于治疗与双相情感障碍相关的重度抑郁发作的单用 lumateperone：一项随机、安慰剂对照试验中的有效性和安全性研究
Christoph U Correll,Suresh Durgam,Susan G Kozauer et al.
Christoph U Correll et al.
This Phase 3, randomized, double-blind, placebo-controlled study evaluated the efficacy and safety of lumateperone to treat bipolar depression. Patients (18-75 years) with bipolar I or bipolar II disorder experiencing a major depressive epi...
Efficacy, suicidality, tolerability, and acceptability of selective serotonin reuptake inhibitors and serotonin-norepinephrine reuptake inhibitors for children and adolescents with anxiety disorders: a systematic review and meta-analysis [0.03%]
选择性五羟色胺再摄取抑制剂和五羟色胺-去甲肾上腺素再摄取抑制剂治疗儿童及青少年焦虑障碍的有效性、自杀风险、耐受性和接受度：系统评价和网络 Meta 分析
Nuntaporn Karawekpanyawong,Chawanun Charnsin,Sirijit Suttajit et al.
Nuntaporn Karawekpanyawong et al.
This systematic review and meta-analysis included randomized controlled trials (RCTs) to compare the efficacy, (treatment-emergent) suicidality, tolerability, and acceptability of selective serotonin reuptake inhibitors (SSRIs) and serotoni...
Long-term safety and tolerability of lumateperone 42 mg in patients with bipolar disorder: results from a 6-month open-label extension study [0.03%]
卢马西泮治疗双相障碍患者长期安全性和耐受性：一项为期6个月开放标签延伸研究结果
Mauricio Tohen,Suresh Durgam,Susan G Kozauer et al.
Mauricio Tohen et al.
This 6-month open-label extension (OLE) period of a Phase 3 placebo-controlled study (NCT02600494) examined the safety of lumateperone in patients with bipolar I or bipolar II depression. Eligible patients completing the placebo-controlled ...
Glucagon-like peptide-1 receptor agonist semaglutide through the lens of psychiatry: a systematic review of potential benefits and risks [0.03%]
从精神病学角度看利拉鲁肽类似物塞马鲁肽的潜在益处和风险：系统综述
Matteo Carminati,Mattia Tondello,Arianna Concina et al.
Matteo Carminati et al.
Semaglutide (SEM), a long-acting glucagon-like peptide-1 receptor agonist, affects neural circuits regulating food intake and satiety, and it provides neuroprotective effects; however, SEM may influence psychological functioning, possibly l...
Raising awareness for adult ADHD diagnosis: addressing diagnostic challenges, comorbidities, and the path to proper recognition [0.03%]
提高成人ADHD诊断意识：应对诊断挑战、共病及正确认识的道路
Camilla Elefante,Giulio Perugi
Camilla Elefante
Innovations and challenges in antipsychotic treatments and external modulating factors [0.03%]
抗精神病药物治疗的创新与挑战及外调因素的影响问题
Alessandro Serretti
Alessandro Serretti